{"entity":{"id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","aka":["RaPTR-101"],"tldr":"A phase 1/2 trial of RPTR-1-201 in advanced solid tumours, run by Repertoire Immune Medicines, now recruiting.","summary":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07293754 by Repertoire Immune Medicines, with 150 participants planned, started 2025-12-12 and due to reach its primary completion in 2028-12-15. Interventions recorded: RPTR-1-201 and PD-1 / PD-L1 monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07293754","url":"https://clinicaltrials.gov/study/NCT07293754"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07293754","phase":"1/2","setting":"A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors","sponsor":"Repertoire Immune Medicines","started":"2025-12-12","startedType":"actual","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07293754/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}]}}